Urokinase system expression in gastric carcinoma

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cancer

• Publication date

  2006-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.21682PMID 16435385
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer

  2005cited by this paper
• Complications of an Addisonian crisis

  2004cited by this paper
• Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication

  2004cited by this paper
• The Gastritis Connection: Prevention and Early Detection of Gastric Neoplasms

  2003cited by this paper
• Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

  2002cited by this paper
• Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow.

  2002cited by this paper
• Is type III intestinal metaplasia an obligatory precancerous lesion in intestinal‐type gastric carcinoma?

  2001cited by this paper
• Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo.

  2001cited by this paper
• Helicobacter pylori interactions with plasminogen.

  2000cited by this paper
• Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay.

  1998cited by this paper
• Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer.

  1997cited by this paper
• Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer.

  1997cited by this paper
• Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease.

  1997cited by this paper
• Gastric mucosal plasminogen activators inHelicobacter pylori infection

  1996cited by this paper
• Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.

  1995cited by this paper
• Co‐expression of urokinase, urokinase receptor and PAI‐1 is necessary for optimum invasiveness of cultured lung cancer cells

  1995cited by this paper
• Urokinase plasminogen activator receptor, beta 2-integrins, and Src- kinases within a single receptor complex of human monocytes

  1995cited by this paper
• Individual development and uPA–receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer

  1995cited by this paper
• Protease nexin-1-urokinase complexes are internalized and degraded through a mechanism that requires both urokinase receptor and alpha 2-macroglobulin receptor.

  1994cited by this paper
• Urokinase receptor and colorectal cancer survival.

  1994cited by this paper
• Urokinase receptor and colorectal cancer survival.

  1994cited by this paper
• Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.

  1994cited by this paper
• Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer.

  1994cited by this paper
• Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.

  1994cited by this paper
• Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.

  1993cited by this paper
• Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness

  1993cited by this paper
• The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma.

  1991cited by this paper
• Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor.

  1991cited by this paper
• Plasminogen Activation by Receptor-Bound Urokinase

  1991cited by this paper
• Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.

  1990cited by this paper
• Plasminogen activators in endoscopic biopsies as indicators of gastrointestinal cancer: comparison with resection specimens.

  1989cited by this paper
• THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.

  1965cited by this paper
• Handbuch der speziellen pathologischen anatomie und histologie

  1931cited by this paper
• Stomach Carcinoma

  1915cited by this paper

• Epithelial-to-mesenchymal transition (EMT) and cancer metastasis: the status quo of methods and experimental models 2025

  2025cites this paper
• Good or bad: Paradox of plasminogen activator inhibitor 1 (PAI-1) in digestive system tumors.

  2023cites this paper
• Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer

  2022cites this paper
• TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR

  2022cites this paper
• Identification of the angiogenesis related genes for predicting prognosis of patients with gastric cancer

  2021cites this paper
• Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma

  2021cites this paper
• Seroprevalence of Helicobacter pylori/CagA Antibodies in Guatemalan Gastric Cancer Patients: Association of Seropositivity with Increased Plasma Levels of Pepsinogens but not Soluble Urokinase Plasminogen Activator Receptor.

  2020cites this paper
• The Role of the Urokinase-Type Plasminogen Activator System In Tumor Progression

  2019cites this paper
• Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications

  2018influential citation
• Priming the seed: Helicobacter pylori alters epithelial cell invasiveness in early gastric carcinogenesis

  2018cites this paper
• [The urokinase-type plasminogen activator system and its role in tumor progression].

  2018cites this paper
• Relevance of the plasminogen activation system in the pathogenesis and progression of gastric cancer

  2018cites this paper
• The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis

  2017cites this paper
• Expression of the anaphylatoxin C5a receptor in gastric cancer: implications for vascular invasion and patient outcomes

  2016cites this paper
• PAI-1 deficiency increases the trophic effects of hypergastrinemia in the gastric corpus mucosa.

  2016cites this paper
• Endoscopic biopsies from gastrointestinal carcinomas and their suitability for molecular analysis: a review of the literature and recommendations for clinical practice and research

  2015cites this paper
• An investigation of novel biomarkers of gastric mucosal preneoplasia

  2015cites this paper
• MECHANISMS OF TUMOR PROGRESSION

  2014cites this paper
• Impact of proteolytic enzymes in colorectal cancer development and progression.

  2014cites this paper
• Soluble urokinase-type plasminogen activator receptor and ferritin concentration in patients with advanced alimentary tract carcinoma. Relationship to localization, surgical treatment and the stage of the disease--preliminary report.

  2014cites this paper
• Involvement of Urokinase‐Type Plasminogen Activator System in Cancer: An Overview

  2014cites this paper
• From Plasminogen to Plasmin: Role of Plasminogen Receptors in Human Cancer

  2014cites this paper
• Protein-protein interactions of the nuclear receptor NR4A2

  2014cites this paper
• Positive nuclear expression of KLF8 might be correlated with shorter survival in gastric adenocarcinoma.

  2014cites this paper
• Role of Urokinase Receptor in Tumor Progression and Development

  2013cites this paper
• The role of plasminogen activator inhibitor-1 in gastric mucosal protection

  2013cites this paper
• Reverse-Phase Protein Array Analysis to Identify Biomarker Proteins in Human Pancreatic Cancer

  2013cites this paper
• Gene Signatures in Gastric Cancer

  2012cites this paper
• Urokinase plasminogen activator receptor on invasive cancer cells: A prognostic factor in distal gastric adenocarcinoma

  2012cites this paper
• Biological activity of Helicobacter pylori components in mammalian cells: is it independent of proteinase-activated receptors?

  2012cites this paper
• Role of Urokinase Plasminogen Activator Receptor in Gastric Cancer: A Potential Therapeutic Target

  2012cites this paper
• ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer

  2012cites this paper
• The effect of gender on Helicobacter pylori and gastric cancer

  2011cites this paper
• Gastrin stimulates expression of plasminogen activator inhibitor-1 in gastric epithelial cells.

  2011cites this paper
• Clinical applications of the urokinase receptor (uPAR) for cancer patients.

  2011cites this paper
• Genomic and genetic alterations influence the progression of gastric cancer.

  2011cites this paper
• Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules

  2010cites this paper
• Urokinase plasminogen activator receptor is expressed in invasive cells in gastric carcinomas from high‐ and low‐risk countries

  2010cites this paper
• Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1

  2010cites this paper
• Translational research on u-PAR.

  2010cites this paper
• Cancer-specific MALDI-TOF profiles of blood serum and plasma: biological meaning and perspectives.

  2010cites this paper
• Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1

  2010cites this paper
• Current Clinical Pathology

  2010cites this paper
• The urokinase plasminogen activator system: a target for anti-cancer therapy.

  2009cites this paper
• Selective Growth Inhibition of Cancer Cells by L-Methioninase-Containing Fusion Protein Targeted to the Urokinase Receptor

  2009cites this paper
• Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity.

  2009cites this paper
• The role of plasminogen-plasmin system in cancer.

  2009cites this paper
• Urokinase receptor, MMP‐1 and MMP‐9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies

  2009cites this paper
• Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR).

  2009cites this paper
• Induction of Akt activity by chemotherapy confers acquired resistance.

  2009cites this paper
• Increased expression of the urokinase plasminogen activator system by Helicobacter pylori in gastric epithelial cells

  2008cites this paper
• The tumor marker and prognostic impact of cathepsin B , cathepsin L , urokinase-type plasminogen activator and its inhibitor type-1 in colorectal cancer

  2008cites this paper
• Regulation of programmed cell death by plasminogen activator inhibitor type 1 (PAI-1)

  2008cites this paper
• Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers

  2008influential citation
• Plasminogen‐induced aggregation of PANC‐1 cells requires conversion to plasmin and is inhibited by endogenous plasminogen activator inhibitor‐1

  2008cites this paper
• The urokinase receptor (u‐PAR)—a link between tumor cell dormancy and minimal residual disease in bone marrow?  

  2008cites this paper
• Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway.

  2008cites this paper
• Helicobacter pylori Infection Stimulates Plasminogen Activator Inhibitor 1 Production by Gastric Epithelial Cells

  2008cites this paper
• Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer

  2008cites this paper
• Loss of programmed cell death 4 expression marks adenoma‐carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer

  2007cites this paper
• Influence of L-methioninase targeted to the urokinase receptor on the proliferation and motility of lung and prostate cancer cells.

  2007cites this paper
• Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model

  2007cites this paper
• The Potential Role of Intrinsic Hypoxia Markers as Prognostic Variables in Cancer

  2007cites this paper
• Comparative Genomics on the Basal Mammalian Urokinase Receptor-Promoter and Impact for Potential in Vivo/Clinical Relevance in Cancer

  2007cites this paper
• Urokinase-Receptor (u-PAR)–An Essential Player in Multiple Games of Cancer: A Review on Its Role in Tumor Progression, Invasion, Metastasis, Proliferation/dormancy, Clinical Outcome and Minimal Residual Disease

  2006cites this paper
• Helicobacter pylori and gastric cancer

  2006cites this paper